Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience.
Yıldız R, Demirel YS, Mungan VD, Aydın Ö, Sin BA, Ağca M, Bavbek S. Yıldız R, et al. Among authors: sin ba. Tuberk Toraks. 2022 Sep;70(3):231-241. doi: 10.5578/tt.20229702. Tuberk Toraks. 2022. PMID: 36164947 Free article. English.
CONCLUSIONS: The incidence of COVID-19 among patients with asthma and urticaria on mepolizumab and omalizumab was higher compared to studies from other countries. The disease course appeared mild in patients receiving long-term biological therapy....
CONCLUSIONS: The incidence of COVID-19 among patients with asthma and urticaria on mepolizumab and omalizumab was higher compared to studies …
Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?
Korkmaz ET, Aydın O, Mungan D, Sin BA, Demirel YS, Bavbek S. Korkmaz ET, et al. Among authors: sin ba. Eur Ann Allergy Clin Immunol. 2024 Jan;56(1):26-33. doi: 10.23822/EurAnnACI.1764-1489.261. Epub 2022 Jul 18. Eur Ann Allergy Clin Immunol. 2024. PMID: 35850503 Free article.
We aimed to evaluate the outcomes of reducing the omalizumab dose in patients with ABPA who were on long-term omalizumab treatment. Methods. Once asthma was controlled, two approaches were used to reduce total monthly omalizumab dose: 1) both extending dose intervals from …
We aimed to evaluate the outcomes of reducing the omalizumab dose in patients with ABPA who were on long-term omalizumab treatment. M …
Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19.
Erkoç M, Öztürk BÖ, Mungan D, Öztuna D, Bavbek S, Demirel YS, Aydın Ö, Sin BA. Erkoç M, et al. Among authors: sin ba. Asia Pac Allergy. 2022 Jan 24;12(1):e6. doi: 10.5415/apallergy.2022.12.e6. eCollection 2022 Jan. Asia Pac Allergy. 2022. PMID: 35174057 Free PMC article.
AIT requires repeated contact between patient and physician or nurse in the hospital. Because it is a long-term treatment, compliance is essential issue to obtain maximal efficacy. ...
AIT requires repeated contact between patient and physician or nurse in the hospital. Because it is a long-term treatment, compliance …
Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases.
Celebi Sozener Z, Gorgulu B, Mungan D, Sin BA, Misirligil Z, Aydin O, Bavbek S. Celebi Sozener Z, et al. Among authors: sin ba. World Allergy Organ J. 2018 Dec 3;11(1):39. doi: 10.1186/s40413-018-0217-0. eCollection 2018. World Allergy Organ J. 2018. PMID: 30524647 Free PMC article.
Our aim was to evaluate the clinical and functional effectiveness of omalizumab in patients with EGPA in long-term follow-up. METHODS: This study was a retrospective chart review of patients with EGPA who were treated with omalizumab injections between May 2012 and April 2 …
Our aim was to evaluate the clinical and functional effectiveness of omalizumab in patients with EGPA in long-term follow-up. METHODS …
Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
Soyyigit S, Guloglu D, Ikinciogullari A, Secil D, Oztuna D, Mungan D, Misirligil Z, Sin BA. Soyyigit S, et al. Among authors: sin ba. Ann Allergy Asthma Immunol. 2016 Mar;116(3):244-251.e2. doi: 10.1016/j.anai.2016.01.002. Ann Allergy Asthma Immunol. 2016. PMID: 26945497 Clinical Trial.
BACKGROUND: There is a continuing debate about whether monoallergen subcutaneous immunotherapy (SCIT) is able to modulate immune and clinical responses toward main causal allergen in polysensitized patients. OBJECTIVE: To investigate short-term immunologic changes and clin …
BACKGROUND: There is a continuing debate about whether monoallergen subcutaneous immunotherapy (SCIT) is able to modulate immune and clinica …
Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases.
Aydın Ö, Sözener ZÇ, Soyyiğit Ş, Kendirlinan R, Gençtürk Z, Mısırlıgil Z, Mungan D, Sin BA, Demirel YS, Çelik GE, Bavbek S. Aydın Ö, et al. Among authors: sin ba. Allergy Asthma Proc. 2015 Nov-Dec;36(6):493-500. doi: 10.2500/aap.2015.36.3909. Allergy Asthma Proc. 2015. PMID: 26534756
OBJECTIVE: To evaluate the clinical and functional effectiveness of omalizumab in patients with asthma and ABPA in long-term follow-up. METHODS: The study was conducted as a retrospective chart review of patients with ABPA who were treated with omalizumab injections betwee …
OBJECTIVE: To evaluate the clinical and functional effectiveness of omalizumab in patients with asthma and ABPA in long-term follow-u …
Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?
Kepil Özdemir S, Sin BA, Güloğlu D, İkincioğulları A, Gençtürk Z, Mısırlıgil Z. Kepil Özdemir S, et al. Among authors: sin ba. Int Arch Allergy Immunol. 2014;164(3):237-45. doi: 10.1159/000365628. Epub 2014 Aug 21. Int Arch Allergy Immunol. 2014. PMID: 25170594 Clinical Trial.
BACKGROUND: An aluminum hydroxide-adsorbed depot allergoid preparation of six-grass pollen allergens has been developed for short-term preseasonal immunotherapy in pollinosis. However, only limited knowledge exists about its immunological and clinical effects. The aim of t …
BACKGROUND: An aluminum hydroxide-adsorbed depot allergoid preparation of six-grass pollen allergens has been developed for short-term …
Churg-Strauss syndrome: a new endotype of severe asthma? Results of 14 Turkish patients.
Yılmaz İ, Çelik G, Aydın Ö, Özdemir SK, Soyyiğit Ş, Sözener Z, Özgüçlü S, Atasoy Ç, Düzgün N, Mungan D, Sin B, Demirel YS, Mısırlıgil Z. Yılmaz İ, et al. Among authors: sin b. Clin Respir J. 2015 Jul;9(3):350-8. doi: 10.1111/crj.12154. Epub 2014 May 19. Clin Respir J. 2015. PMID: 24761830
OBJECTIVE: The aim of this study was to evaluate the clinical and serological features of the disease, the treatment, and long-term follow-up details, and to investigate possible etiological factors of Turkish CSS patients. ...
OBJECTIVE: The aim of this study was to evaluate the clinical and serological features of the disease, the treatment, and long-term f …